Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New tech aims to prevent low blood sugar in seniors with diabetes

NCT ID NCT03078491

Disease control Sponsor: Joslin Diabetes Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether an enhanced continuous glucose monitor (eCGM) linked to a decision-support system can help older adults (65+) with type 1 diabetes manage their blood sugar. The system automatically uploads glucose, insulin, and activity data to give personalized insulin dose recommendations. The goal was to reduce time spent in dangerously low blood sugar (hypoglycemia). 168 participants were enrolled, and the study compared those using the eCGM system to standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
enhanced continuous glucose monitor (eCGM) with clinical decision support
What this could lead to
If successful, this could provide a practical way for older adults with type 1 diabetes to better control their blood sugar and reduce dangerous low blood sugar episodes.
What could go wrong
This is a completed study, so results are available, but the approach relies on technology that may not work for everyone, and the benefits may not apply to those with very poor glucose control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

168 people

The number who actually took part.

Started

Mar 2017

Finished

Oct 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with age ≥ 65 years * Community-living * Clinical diagnosis of T1D * On multiple insulin injections (≥3 injection/s day) or insulin pump. Exclusion Criteria: * Use of real-time CGM in past 2 years * A1c \> 10% (since individuals with very poor glycemic control usually have barriers to optimal self-care that preclude effective use of technology) * Use of insulin pump that cannot be uploaded for CDS * Unable or unwilling to perform task needed for study participation during the run-in period * Severe vision or hearing impairment that could interfere with study tasks * Need to use acetaminophen on regular basis (since can interfere with CGM accuracy) * Living in an institutional setting (e.g. group homes, nursing homes) * Terminal diseases with life expectancy \< 1 year (e.g. malignancy) * Severe comorbidities that prevent completing outcome measurements (e.g. severe dementia, severe vision impairment, severe functional disabilities, inability to perform basic activities of daily living) * Alcohol or other drug abuse * Conditions that impact wear of CGM (e.g. CHF with edema, skin conditions); and * End stage renal insufficiency (eGFR\<30), or on dialysis (since impact of fluid shift on sensor lag not clearly understood).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypoglycemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypoglycemia type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypoglycemia Older adults Type 1 diabetes mellitus

Contacts and locations

Locations

  • Joslin Diabetes Center

    Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.